kabutan

FunPep Company Limited(4881) Summary

4881
TSE Growth
FunPep Company Limited
87
JPY
0
(0.00%)
Jan 29, 3:04 pm JST
0.56
USD
Jan 29, 1:04 am EST
Result
PTS
outside of trading hours
87.1
Jan 29, 3:12 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.67
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
88 JPY 0.57 USD
Previous Close Jan 28
87 JPY 0.57 USD
High Jan 29, 9:00 am
88 JPY 0.57 USD
Low Jan 29, 9:02 am
87 JPY 0.56 USD
Volume
94,200
Trading Value
8.00M JPY 0.05M USD
VWAP
87.22 JPY 0.57 USD
Minimum Trading Value
8,700 JPY 56 USD
Market Cap
3.53B JPY 0.02B USD
Number of Trades
48
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
211
1-Year High May 20, 2025
2,945
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 3,513,700
Jan 16, 2026 0 3,113,800
Jan 9, 2026 0 3,204,200
Dec 26, 2025 0 3,234,000
Dec 19, 2025 0 3,181,400
Company Profile
FunPep Company Limited is a spin-off from Osaka University's Institute for Protein Research, focusing on research and development of pharmaceuticals using functional peptides.
Sector
Pharmaceuticals
FunPep Company Limited engages in the research and development of pharmaceuticals and other products using functional peptides. The company's strength lies in its proprietary drug discovery platform technology "STEP UP" for antibody-inducing peptides, enabling the creation of development candidates for various target proteins as alternatives to antibody drugs. Additionally, FunPep is advancing the development of SR-0379, a treatment for skin ulcers. The company aims to generate new development candidates through collaborative research with universities and promotes development through partnerships with pharmaceutical companies. In the future, FunPep aspires to achieve significant profit growth through royalty income from the commercialization of its development products. The company's mission is to contribute to society by developing new pharmaceuticals that help reduce medical costs and patient burden.